Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Master Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies as Assessed by Biomarker Status and Cognition

NCT07177352 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT07177352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07177352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Master Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies as Assessed by Biomarker Status and Cognition
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Recruiting
Start date
July 2, 2025
Completion date
July 31, 2035
Enrollment
80,000 (estimated)
Sites
230

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimers disease